(Q46571276)

23 December 2017

title

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection (English)

1 reference

23 December 2017

main subject

multiple drug resistance

1 reference

1 reference

1

Thomas B Campbell

1 reference

23 December 2017

Daniel Kuritzkes

10

object named as

Daniel R Kuritzkes

1 reference

23 December 2017

author name string

Nancy S Shulman

2

1 reference

23 December 2017

Steven C Johnson

3

1 reference

23 December 2017

Andrew R Zolopa

4

1 reference

23 December 2017

Russell K Young

5

1 reference

23 December 2017

Lane Bushman

6

1 reference

23 December 2017

Courtney V Fletcher

7

1 reference

23 December 2017

E Randall Lanier

8

1 reference

23 December 2017

Thomas C Merigan

9

1 reference

23 December 2017

language of work or name

English

0 references

publication date

7 June 2005

1 reference

23 December 2017

Clinical Infectious Diseases

published in

1 reference

23 December 2017

volume

41

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

236-242

1 reference

23 December 2017

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

cites work

1 reference

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

Development and Significance of the HIV-1 Reverse Transcriptase M184V Mutation During Combination Therapy With Lamivudine, Zidovudine, and Protease Inhibitors

21 January 2018

1 reference

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

21 January 2018

1 reference

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

21 January 2018

1 reference

Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation

21 January 2018

1 reference

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

21 January 2018

1 reference

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

21 January 2018

1 reference

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

21 January 2018

1 reference

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Workin

21 January 2018

1 reference

Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA.

21 January 2018

1 reference

Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection

21 January 2018

1 reference

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/430709

1 reference

23 December 2017

1 reference

23 December 2017